ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1494

CD40 Signaling Results in Microvascular Endothelial Dysfunction: A Possible Clue to the Pathogenesis of Scleroderma Vasculopathy

Bashar Kahaleh1 and Yongqing Wang2, 1Medicine/Rheumatology, University of Toledo, Toledo, OH, 2Medicine, University of Toledo, Toledo, OH

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Apoptosis, endothelial cells and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud’s – Pathogenesis, Animal Models and Genetics

Session Type: Abstract Submissions (ACR)

Background/Purpose: Increased expression of CD40 in SSc- Microvascular Endothelial Cells (MVEC) was noted on a gene expression array and increased concentrations of soluble CD40 ligand (sCD40L) was reported in scleroderma. In this study we investigated the effect of CD40 ligation on MVEC apoptosis, activation and dysfunction. 

Methods: MVEC were isolated from involved SSc skin and from matched healthy control subjects. MVEC apoptosis was assessed by flow cytometry, caspases3/7 activity and cell viability. MVEC genes expression was determined by real-time-PCR and results were confirmed by western blot analysis. Endothelial permeability was assessed by FITC-Dextran permeability assay.

Results:

Significant increase in CD40 expression of was noted in SSc-MVEC (3.2 folds ± 0.3 in SSc vs. control MVEC). Similar increase in expression level was noted in SS skin biopsies (2.4 folds ± 0.3 in SSc skin vs. control skin biopsies, n=3 each).

The addition of CD40 ligand to MVEC resulted in the following observations:

  1. Reduction in nitric oxide synthase (NOS3) expression (80%±6 reduction in control-MVEC and 82%± 8 in SSc-MVEC, mean 4 cell lines ±SD) and in prostacyclin synthase (PTGS1), 64% ± 3.0 reduction in control-MVEC and 79% ± 4.5 reduction in SSc- MVEC, mean 4 cell lines ±SD ). While Endothelin 1 expression was significantly increased by 2.2± 0.12 folds in control MVEC and by 2.8 ±0.31 folds in SSc MVEC.
  2. Increase EC permeability (2.2± 0.3 in control-MVEC and 2.8 ± 0.34 in SSc-MVEC, folds±SD)      
  3. Significant Increase expression of the CC and CXC chemokines including CCL2, interleukin-8, CXCL3, 5, 6 and 9.
  4. Increase expression of IL1B, hepatocyte growth factor and adhesion molecules particularly ICAM1.
  5. Significant down regulation of c-fos induced growth factor (FGIF, vascular endothelial growth factor D), epidermal growth factor, Insulin-like growth factor 1 and metallopeptidase inhibitor TIMP2.
  6. The addition of CD40L to MVEC cultured in 0.5% serum resulted in a dose dependent apoptosis of MVEC. SSc-MVEC were more susceptible to apoptosis than control MVEC, thus at 10 μg concentration of CD40L , MVEC apoptosis was 45% ± 5 and 20% ± 3 in SSc vs. control MVEC respectively (mean ± SD of 4 cell lines). Apoptosis was confirmed by increase caspase 3/7 activity 2.2 folds in control and 3.0 folds in SSc-MVEC.

Conclusion:

The study demonstrates increase expression of CD40 in SSc skin and in SSc-MVEC. CD40 ligation led to reduce expression of vasodilatory and increase expression of vasoconstrictive genes. Moreover, addition of CD40L increased endothelial permeability and the acquisition of an activated/ dysfunctional phenotype in association with increase MVEC apoptosis. In all instances, SSc MVEC were more susceptible to CD40 signaling effects than control MVEC. The results suggest that the blockade of CD40/CD40 ligand interaction could be an effective therapeutic strategy in SSc.


Disclosure:

B. Kahaleh,
None;

Y. Wang,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cd40-signaling-results-in-microvascular-endothelial-dysfunction-a-possible-clue-to-the-pathogenesis-of-scleroderma-vasculopathy/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology